Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliance under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 201517-11-2022
17-11-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recording of Earnings call pertaining to the Financial Results for the quarter and half year ended September 30, 202216-11-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Unaudited Financial Results for the quarter and half year ended September 30, 202215-11-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Resignation of Director
This is to inform you that Mr. Deepak Calian Vaidya (DIN: 00337276), Non-Executive Director of the Company has communicated his decision to step down from Directorship of the Company with effect from closing business hours of November 14, 2022, due to pre-occupation. Mr. Vaidya was associated with Strides since January 1998 and has made significant contributions in laying a solid foundation for taking Strides to the next level of growth with compliance and integrity as key pillars. Strides has benefited immensely by his experience and guidance at many junctures. Board of Directors at their meeting held today placed on record their sincere appreciation for the valuable contributions made by Mr. Vaidya during his long and distinguished association with the Company and wished him the very best. Information as required under Regulation 30 of Listing Regulations, read with SEBI Circular No. CIR/ CFD/ CMD/ 4/ 2015 dated September 9, 2015 is enclosed.14-11-2022
Q2FY23 Quarterly Result Announced for Strides Pharma Science Ltd.
Strides Pharma Science announced Q2FY23 results: Q2FY23: Consolidated EBITDA at Rs 1,006 million, up 100%+ YoY, led by healthy gross margin expansion and operating leverage Consolidated revenues at Rs 8,995 million, up 22% YoY Business returns to positive adjusted PAT of Rs 306 million US Business reports its best-ever quarterly performance at $60 million revenues Significant optimization of network and operating costs resulted in improved operating leverage Strong order book and improved operating margins to enable free cash flow generation and achieve net debt to exit by Q4FY23 Arrotex Deferred consideration to be received ahead of the Contractual due date Arun Kumar, Founder, Managing Director, and Executive Chairperson, commented on the performance and said, “We continue to make good strategic progress across all our key businesses with a sharper focus on execution and cost competitiveness. We have delivered an improved sequential performance led by gross margin expansion. Our cost control measures have started yielding results and have enabled strong operating leverage during the quarter Our US business has reported its best-ever quarterly performance, driven by improved market share for the base portfolio, an uptick in the acquired portfolio at Chestnut Ridge, and contribution from new launches. We expect the new launch momentum to pick up in the coming quarters as we leverage a vast portfolio of over 100 approved products undergoing cost improvements and manufacturing site changes in the near term. We have completed the strategic review of the Other Regulated Markets (ORM) business. We have decided to exit several low-margin product lines resulting in a lower topline during the quarter. The long-term outlook for the ORM business continues to be robust, and we expect to get to the historical levels of revenues with superior gross margins as early as Q3FY23 With all the levers in place, we expect to continue our growth momentum in coming quarters with a focus on improved margins, free cash flow generation, and significant deleveraging of our balance sheet, targeting a net debt to EBITDA of less than three times.” Result PDF14-11-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of shares under Strides ESOP Plan 201614-11-2022
Strides Pharma Science Ltd - 532531 - Grant Of Options Under Strides ESOP Plan 2016
Pursuant to the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held today i.e., November 14, 2022, has granted 42,500 stock options to eligible employees under the Strides ESOP Plan 2016 at Rs. 240/- per option (exercise price). The shares covered by such options are 42,500 equity shares. The vesting period of these options are in a phased manner over a period of 3 years. The options are exercisable within a period of 12 months (exercisable in not more than two tranches) from the date of vesting.14-11-2022
Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended September 30, 2022
Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 202214-11-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis.14-11-2022
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call for discussion of un-audited financial results for the quarter and half-year ended September 30, 2022.11-11-2022